Could a common antioxidant ease early psychosis symptoms?
NCT ID NCT05142735
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether N-acetylcysteine (NAC), a safe antioxidant supplement, can reduce early psychosis-like symptoms in 90 people at clinical high risk for schizophrenia. Participants take NAC for 8 weeks, and researchers measure changes in symptoms and brain activity. The goal is to find a well-tolerated treatment option for those with early warning signs.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRODROMAL SCHIZOPHRENIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre for Addiction and Mental Health
RECRUITINGToronto, Ontario, M5T 1R8, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Brain training from home: could a smartphone app sharpen thinking in early psychosis?
- Can a quick brain zap ease schizophrenia symptoms?
- Could a brain booster stop schizophrenia before it starts?
- New Step-by-Step care model aims to halt psychosis in its tracks
- Can family therapy prevent psychosis in At-Risk youth?
- Brain training may boost social skills in at-risk teens